Innocare Pharma

Innocare Pharma's Carbon Emissions and Climate Commitments

Innocare Pharma, a pharmaceutical preparation manufacturing company headquartered in China (CN), has reported its carbon emissions for recent years, focusing primarily on Scope 1 and Scope 2 emissions.

For the year 2023, Innocare Pharma's total reported emissions were approximately 12,134,540 kg CO2e. This figure comprises approximately 19,950 kg CO2e of Scope 1 emissions and approximately 12,114,590 kg CO2e of Scope 2 emissions.

In 2022, the company reported total emissions of approximately 9,835,800 kg CO2e, all attributed to Scope 2. Scope 1 emissions for 2022 were not reported as having data.

For 2021, Innocare Pharma reported total emissions of approximately 9,236,400 kg CO2e, which were entirely Scope 2 emissions. Similar to 2022, Scope 1 emissions data was not available for this year.

In 2020, the company's emissions totalled approximately 2,476,590 kg CO2e, consisting of Scope 2 emissions. Scope 1 emissions for 2020 were reported as zero.

Innocare Pharma's disclosed emissions data currently excludes Scope 3 emissions, with a noted missing data point for purchased goods and services. The company's provided information does not detail any specific absolute reduction targets or achievements in its climate commitments. The available documentation indicates that the company is focused on reporting Scope 1 and 2 emissions.